Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Polycythemia Vera 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Myeloproliferative Disorders 1Hodgkin Disease 1

Interventions

fludarabine phosphate 31Cyclophosphamide 27Mycophenolic Acid 22Whole-Body Irradiation 21Tacrolimus 21ruxolitinib 19Peripheral Blood Stem Cell Transplantation 19Busulfan 19Antilymphocyte Serum 16fludarabine 14Melphalan 12Methotrexate 11Cyclosporine 10thymoglobulin 9Cord Blood Stem Cell Transplantation 7Sirolimus 6Radiotherapy 6Etoposide 6Azacitidine 6Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclosporins 4pomalidomide 3parsaclisib 3Surveys and Questionnaires 3Rituximab 3Prednisone 3Filgrastim 3Cytarabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Primary Myelofibrosis × givinostat × Clear all
NCT00606307 2019-12-03

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Italfarmaco

Phase 2 Completed
29 enrolled 8 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01901432 2019-07-30

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Italfarmaco

Phase 1/2 Completed
48 enrolled 28 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡